75446-59-2

Usage

Uses

Used in Organic Synthesis:
(BIPHENYL-4-CARBONYL)-AMINO]-ACETIC ACID is used as a starting material in organic synthesis for the production of various derivatives. Its unique structure and functional groups make it a valuable component in the creation of new compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (BIPHENYL-4-CARBONYL)-AMINO]-ACETIC ACID is utilized as a starting material for the development of new drugs. Its potential anti-inflammatory and antioxidant properties make it a subject of interest for researchers seeking to create novel therapeutic agents.
Used in the Development of Therapeutic Agents:
(BIPHENYL-4-CARBONYL)-AMINO]-ACETIC ACID is used as a key component in the development of new therapeutic agents due to its potential anti-inflammatory and antioxidant properties. These properties make it a promising candidate for the treatment of various conditions, including inflammatory diseases and oxidative stress-related disorders.
Used in the Synthesis of Biologically Active Molecules:
(BIPHENYL-4-CARBONYL)-AMINO]-ACETIC ACID is employed as a building block in the synthesis of biologically active molecules. Its unique structure and functional groups contribute to the creation of molecules with specific biological activities, making it an essential component in the development of new pharmaceuticals and other bioactive compounds.

InChI:InChI=1/C15H13NO3/c17-14(18)10-16-15(19)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9H,10H2,(H,16,19)(H,17,18)/p-1

Upstream product

• 14002-51-8 4-biphenyl-carboxylic acid chloride 
• 56-40-6 glycine 
• 18815-75-3 N-(4-bromobenzyl-1-carbonyl)-glycine 
• 98-80-6 phenylboronic acid 
• 349399-09-3 [(biphenyl-4-carbonyl)-amino]-acetic acid ethyl ester 
• 92-92-2 biphenyl-4-carboxylic acid 

Downstream Products

• 92497-78-4 2-biphenyl-4-yl-4H-oxazol-5-one 
• 13853-41-3 2-biphenyl-4-yl-4-(2,6-dimethyl-pyran-4-ylidene)-4H-oxazol-5-one 
• 13853-43-5 4-(2,6-Diphenyl-pyranyliden)-2-(p-biphenylyl)-oxazolon-5 
• 1188372-04-4 biphenyl-4-carboxylic acid (2-{4-[(2-chloro-phenyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-amide 
• 1188371-99-4 biphenyl-4-carboxylic acid {2-[4-(2-bromophenoxy)piperidin-1-yl]-2-oxoethyl}amide 
• 1188371-98-3 biphenyl-4-carboxylic acid {2-oxo-2-[4-(2-trifluoromethylphenoxy)piperidin-1-yl]ethyl}amide 
• 1188372-03-3 biphenyl-4-carboxylic acid (2-{4-[methyl-(2-trifluoromethylphenyl)amino]piperidin-1-yl}-2-oxoethyl)amide 
• 1188372-01-1 biphenyl-4-carboxylic acid {2-[4-(2-chlorophenylamino)piperidin-1-yl]-2-oxoethyl}amide 
• 1188372-02-2 biphenyl-4-carboxylic acid {2-oxo-2-[4-(2-trifluoromethylphenylamino)piperidin-1-yl]ethyl}amide 
• 1188372-00-0 biphenyl-4-carboxylic acid {2-[4-(2-bromophenylamino)piperidin-1-yl]-2-oxoethyl}amide 
• 75446-63-8 4-benzylidene-2-biphenyl-4-yl-4H-oxazol-5-one 
• 101600-66-2 4-ethylidene-2-biphenyl-4-yl-4H-oxazol-5-one 

Relevant academic research and scientific papers

Synthesis, biological evaluation and in silico investigation of novel functionalized imidazole-based KDM6 inhibitors

Epigenetic markers of the cellular genome are major controllers of the transcriptional level of various genes in physiological and pathological states. These markers are written and erased by epigenetic factors which have been recently studied as potentia

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

Fluorous-silica-supported perfluoro-tagged palladium complexes catalyze Suzuki couplings in water

Different Pd-complexes (see 2a-d and 3) with and without perfluoroalkyl tags were deposited on fluorous reversed-phase silica 1 and unmodified silica gel. These supported complexes were successfully used as precatalysts for the Suzuki reaction in H2O. H2O-Soluble aryl bromides were easily converted to the corresponding biphenyls. Although none of the complexes is H2O-soluble, the active catalyst is most likely homogeneously dissolved. Nevertheless, the Pd-leaching into the product was low.

5,6-epoxy-7-oxabicycloheptane substituted diamide prostaglandin analogs

5,6-Epoxy-7-oxabicycloheptane substituted diamide prostaglandin analogs are provided having the structural formula STR1 wherein A is --CH=CH-- or --CH2 --CH2 --; n is 1 to 5; R is CO2 H, CO2 alkyl, CO2 alkali metal, CO2 polyhydroxyamine salt or STR2 q is 1 to 12; and R1 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, STR3 (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

7-thiabicycloheptane substituted diamide and its congener prostaglandin analogs

7-Thiabicycloheptane substituted diamide and congener prostaglandin analogs are provided having the structural formula STR1 wherein m is 1 to 4; A is --CH=CH-- or --CH2 --CH2 --; n is 1 to 5; R is CO2 H, CO2 alkyl, CO2 alkali metal, CO2 polyhydroxyamine salt, --CH2 OH, STR2 wherein R3 and R4 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R3 and R4 being other than hydroxy and lower alkoxy; p is 1 to 4; Z is STR3 q is 1 to 12; R1 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, STR4 (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Bicycloheptane substituted diamide and its congener prostaglandin analogs

Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula STR1 wherein m is 0 to 4; A is --CH=CH-- or --CH2 --CH2 --; n is 1 to 5; Q is --CH=CH--, --CH2 --, STR2 or a single bond; R is CO2 H, CO2 alkyl, CO2 alkali metal, CO2 polyhydroxyamine salt, --CH2 OH, STR3 wherein R4 and R5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R4 and R5 being other than hydroxy and lower alkoxy; p is 1 to 4; R1 is H or lower alkyl; q is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, STR4 (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease

7-Oxabicycloheptane α-substituted ketone prostaglandin analogs are provided having the structural formula STR1 wherein m is 0 to 4; A is --CH=CH-- or --CH2 --CH2 --; n is 1 to 5; X is halogen, alkanoyloxy or hydroxy; p is 1 to 4; R1 is H or lower alkyl; q is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, amino, alkylamino, or arylamino. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

7-OXABICYCLOHEPTANE SUBSTITUTED DIAMIDE AND ITS CONGENER PROSTAGLANDIN ANALOGS USEFUL IN THE TREATMENT OF THROMBOTIC DISEASE

7-Oxabicycloheptane substituted amide prostaglandin analogs are provided having the structural formula STR1 wherein m is 0 to 4; A is--CH=CH--or--CH 2--CH 2--; n is 1 to 5; Q is--CH=CH--,--CH 2--, STR2 or a single bond; R is CO 2 H, CO 2 alkyl, CO 2 alkali metal, CO 2 polyhydroxyamine salt,--CH 2 OH, STR3 wherein R. sup.4 and R 5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R 4 and R 5 being other than hydroxy and lower alkoxy; p is 1 to 4; R. sup.1 is H or lower alkyl; q is 1 to 12; R 2 is H or lower alkyl; and R 3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, STR4 (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

SYNTHESIS AND SPECTRAL-LUMINISCENCE PROPERTIES OF 2-ARYL-4-BENZYLIDENE-5-OXAZOLONES

A number of 2-aryl-4-benzylidene-5-oxazolones was obtained by condensation of benzaldehyde with N-acylglycines.The absorption and fluorescence spectra in chloroform at 77 deg K were measured.The spectral characteristics of the investigated and previously

LUMINESCENCE PROPERTIES OF COMPOUNDS CONTAINING BOTH 2,5-DIARYLOXAZOLE AND 5-OXAZOLE UNITS.

Compounds which contain the 2,5-diaryloxazole unit in addition to the oxazolone ring are analyzed concerning the effect of this structural modification on the fluorescence properties of luminophores of the oxazolone series in the solid state and, in view of the intense emission of 2,5-diaryloxazoles in solution, the possibility of preparing 5-oxazolone derivatives that fluoresce in organic solvents is examined.